Abstract
Background
The prognostic impact of isolated lymphovascular invasion (LVI) after radical resection of rectal cancer is controversially discussed. However, it could be relevant to decide for an adjuvant treatment.
Aim
The aim of the analysis was, based on the data of an observational study, to determine the prognostic relevance of the isolated LVI.
Materials and methods
Patients after radical resection of rectal cancer with no hemangioinvasion were subdivided in three groups: I—no LVI, no lymph node metastases (LNM); II—positive LVI, no LNM; III—positive LNM. Five-year local recurrence rate, distant metastases-free and disease-free survival were determined uni- and multivariate.
Results
Patients, n = 846, were studied (I, n = 471; II, n = 75; III, n = 300). The univariate comparison between the groups revealed the following 5-year results: local recurrence rate: 9.4 vs 10.0 vs 14.0%; distant metastases-free survival: 84.1 vs 82.5 vs 49.3%; disease-free survival: 83.2 vs 80.7 vs 45.5%. The differences between groups I and III were significant, but not between groups I and II. The determined higher disease-free survival rate in group II vs group III was significant (P = 0.041), but the differences in local recurrence rate and rate of distant metastases did not reach statistical significance. The multivariate analysis revealed no impact of the isolated LVI on the oncological outcome.
Conclusion
The isolated LVI has no independent prognostic impact on the local recurrence rate and long-term survival after radical resection of rectal cancer. Based on this finding, no indication for an adjuvant treatment in these patients can be derived.
Similar content being viewed by others
References
Wibe A, Syse A, Andersen E, Tretli S, Myrvold HE, Soreide O; on behalf of the Norwegian Rectal Cancer Group (2004) Oncological outcomes after total mesorectal excision for cure for cancer of the lower rectum: anterior vs. abdominoperineal resection. Dis Colon Rectum 47:48–58
Cecil TD, Sexton R, Moran BJ, Heald RJ (2004) Total mesorectal excision results in low local recurrence rates in lymph node-positive rectal cancer. Dis Colon Rectum 45:1145–1150
Heald RJ, Ryall RD (1986) Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1:1479–1482
Park YJ, Park KJ, Park J, Lee KU, Choe KJ, Kim J (1999) Prognostic factors in 2230 Korean colorectal cancer patients: analysis of consecutively operated patients. World J Surg 23:721–726
Greene FL, Stewart AK, Norton HJ (2004) New tumor-node-metastasis staging strategy for node-positive (stage III) rectal cancer: an analysis. J Clin Oncol 22:1778–1784
Wang HS, Liang WY, Lin TC, Chen WS, Jiang JK, Yang SH, Chang SC, Lin JK (2005) Curative resection of T1 colorectal carcinoma: risk of lymph node metastasis and long-term prognosis. Dis Colon Rectum 48:1182–1192
Meyer W, Awad-Allah A, Steinhäuser BB, Jurowich C, Kaiser A, Gebhardt C (2001) Prognostic importance of isolated peritumoral lymphangiosis carcinomatosa in lymph-node-negative colorectal carcinoma. Langenbecks Arch Surg 386:124–131
Meguerditchian AN, Bairati I, Lagace R, Harel F, Kibrite A (2005) Prognostic significance of lymphovascular invasion in surgically cured rectal carcinoma. Am J Surg 189:707–713
Heide J, Krull A, Berger J (2004) Extracapsular spread of nodal metastasis as a prognostic factor in rectal cancer. Int J Radiat Oncol Biol Phys 58:773–778
Law WL, Chu KW (2002) Local recurrence following total mesorectal excision with double-stapling anastomosis for rectal cancers: analysis of risk factors. World J Surg 26:1272–1276
Law WL, Ho JWC, Chan R, Au G, Chu KW (2005) Outcome of anterior resection for stage II rectal cancer without radiation: the role of adjuvant chemotherapy. Dis Colon Rectum 48:218–226
Tang R, Wang JY, Tsao KC, Ho YS (1999) Lymphangiosis as a predictor of outcome in patients with primary diffusely infiltrative adenocarcinoma of the colon and rectum. Arch Surg 134:157–160
Celen O, Yildirim E, Berberoglu U (2004) Factors influencing outcome of surgery for stage I rectal cancer. Neoplasm 51:487–490
Marusch F, Koch A, Schmidt U, Meyer L, Steinert R, Pross M, Köckerling F, Bauer H, Schönleben K, Halbfass HJ, Scheele J, Gastinger I, Lippert H; Studiengruppe “Kolon/Rektum Karzinome (Primärtumor)” (2003) Importance of rectal extirpation for the therapy concept of low rectal cancers. Chirurg 74:341–352
Marusch F, Koch A, Schmidt U, Zippel R, Geissler S, Pross M, Roessner A, Köckerling I, Lippert H (2002) “Colon-/rectal carcinoma” prospective studies as comprehensive surgical quality assurance. Chirurg 73:138–146
Deinlein P, Reulbach U, Stolte M, Vieth M (2003) Risk factors for lymphatic metastasis from pT1 colorectal adenocarcinoma. Pathologe 24:387–393
Law WL, Chu KW (2004) Anterior resection for rectal cancer with mesorectal excision. A prospective evaluation of 622 patients. Ann Surg 240:260–268
Rosenberg R, Friederichs J, Gertler R, Hoos A, Mueller J, Nahrig J, Nekarda H, Siewert JR (2004) Prognostic evaluation and review of immunohistochemically detected disseminated tumor cells in peritumoral lymph nodes of patients with pN0 colorectal cancer. Int J Colorectal Dis 19:430–437
Isaka N, Nozue M, Doy M, Fukao K (1999) Prognostic significance of perirectal lymph node micrometastasis in Dukes’ B rectal carcinoma: an immunohistochemical study by CAM5.2. Clin Cancer Res 5:2065–2068
Charbit L, Peschaud F, Penna C (2005) Lymph nodes in rectal cancer. J Chir (Paris) 142:85–92
Wang C, Zhou ZG, Wang Z, Chen DY, Zheng YC, Zhao PG (2005) Nodal spread and micrometastasis within the mesorectum. World J Gastroenterol 11:3586–3590
Hassan C, Zullo A, Risio M, Rossini FP, Morini S (2005) Histologic risk factors and clinical outcome in colorectal malignant polyp: a pooled-data analysis. Dis Colon Rectum 48:1588–1596
Okabe S, Shia J, Nash G, Wong WD, Guillem JG, Weiser MR, Temple L, Sugihara K, Paty PB (2004) Lymph node metastasis in T1 adenocarcinoma of the colon and rectum. J Gastrointest Surg 8:1032–1039
Mouta Carriera C, Nasser SM, di Tomaso E, Padera TP, Boucher Y, Tomarev SI, Jain RK (2001) LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. Cancer Res 61:8079–8084
Jackson DG (2003) The lymphatics revisited: new perspectives from the hyaluronan receptor LYVE-1. Trends Cardiovasc Med 13:1–7
Sleeman JP, Krishnan J, Kirkin V, Baumann P (2001) Markers for the lymphatic endothelium: in search of the holy grail? Microsc Res Tech 55:61–69
Rodriguez-Niedenfuhr M, Papoutsi M, Christ B, Nicolaides KH, von Kaisenberg CS, Tomarev SI, Wilting J (2001) Prox1 is a marker of ectodermal placodes, endodermal compartments, lymphatic endothelium and lymphangioblasts. Anat Embryol 204:399–406
Wilting J, Papoutsi M, Christ B, Nicolaides KH, von Kaisenberg CS, Borges J, Stark GB, Alitalo K, Tomarev SI, Niemeyer C, Rossler J (2002) The transcription factor Prox1 is a marker for lymphatic endothelial cells in normal and diseased human tissues. FASEB J 16:1271–1273
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Ptok, H., Meyer, F., Steinert, R. et al. No prognostic impact of isolated lymphovascular invasion after radical resection of rectal cancer—results of a multicenter observational study. Int J Colorectal Dis 22, 749–756 (2007). https://doi.org/10.1007/s00384-006-0220-8
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00384-006-0220-8